Search

Your search keyword '"Lewis, Hal"' showing total 194 results

Search Constraints

Start Over You searched for: Author "Lewis, Hal" Remove constraint Author: "Lewis, Hal"
194 results on '"Lewis, Hal"'

Search Results

3. Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate

6. Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors

7. Classification for Big Dataset of Bioacoustic Signals Based on Human Scoring System and Artificial Neural Network

9. Western Region Faculty Institute for Training. Early Education Program for Children with Disabilities. Final Report.

10. Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors

11. Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1

13. Design, Structure–Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors

14. Structure–activity relationship (SAR) studies on substituted N-(pyridin-3-yl)-2-amino-isonicotinamides as highly potent and selective glycogen synthase kinase-3 (GSK-3) inhibitors

15. Structure-Activity Relationship (SAR) Studies on Substituted 2-(Pyridin-2-ylamino)-N-(pyridin-3-yl)isonicotinamide as Highly Potent, Selective and Brain Penetrant Glycogen Synthase Kinase-3 (GSK-3) Inhibitors

16. Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor

17. Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs

18. Core Modifications to the 4-(4,4-Dimethylpiperidinyl) 2,6-Dimethylpyridinyl Class of Hiv-1 Allosteric Integrase Inhibitors

19. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers

21. 70 Jewish leaders, thinkers, and clergy respond to the question: what will be the condition of the Jewish community 50 years from now?

22. RAILROADS AND SLAVERY: Readers Respond

23. Moses and the Journey to Leadership: Timeless Lessons of Effective Management from the Bible and Today's Leaders

24. SGX393 inhibits the CML mutant [Bcr-Abl.sup.T3151] and preempts in vitro resistance when combined with nilotinib or dasatinib

28. Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors

29. Sequence-specific RNA binding by a Nova KH domain: implications for paraneoplastic disease and the fragile X syndrome

32. BrainSTARS: pilot data on a team-based intervention program for students who have acquired brain injury

34. 5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors

35. Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core

37. Initial Clinical Guidelines for Co-Occurring Autism Spectrum Disorder and Gender Dysphoria or Incongruence in Adolescents

39. Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors

40. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors

41. Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents

42. Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop

44. With new technology, nonprofits can achieve longtime missions

49. BrainSTARS

50. SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinib

Catalog

Books, media, physical & digital resources